Apimeds Pharmaceuticals US, Inc. (APUS)

NYSEAMERICAN: APUS · Real-Time Price · USD
1.820
+0.015 (0.83%)
May 22, 2025, 4:00 PM - Market closed
0.83%
Market Cap 21.05M
Revenue (ttm) n/a
Net Income (ttm) -1.50M
Shares Out 11.57M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,071
Open 1.860
Previous Close 1.805
Day's Range 1.730 - 1.860
52-Week Range 1.440 - 4.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 20, 2025

About APUS

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2025
Employees 2
Stock Exchange NYSEAMERICAN
Ticker Symbol APUS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...

10 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading

A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street resear...

Other symbols: AHLAIIANTAETOR
13 days ago - Seeking Alpha

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...

14 days ago - GlobeNewsWire

Inflammation-focused biotech Apimeds Pharmaceuticals US files for a $12 million IPO

Apimeds Pharmaceuticals US, a clinical stage biotech developing a bee venom-based treatment for inflammation, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering.

8 months ago - Renaissance Capital

Apimeds Pharmaceuticals US IPO Registration Document (S-1)

Apimeds Pharmaceuticals US has filed to go public with an IPO on the NYSE American

8 months ago - SEC